治疗糖尿病和肥胖症的胃肠道激素类多受体激动剂研究进展  

Advances in multi-receptor agonists based on gastrointestinal hormones in the treatment of diabetes and obesity

作　　者：王媛[1,2] 康明明 王军军 李晓稳 文良柱 WANG Yuan;KANG Ming-ming;WANG Jun-jun;LI Xiao-wen;WEN Liang-zhu(China Pharmaceutical University,Nanjing 211198,China;Jiangsu Wanbang Pharmaceutical Technology Co.,Ltd.,Xuzhou 221004,China)

机构地区：[1]中国药科大学,南京211198 [2]江苏万邦医药科技有限公司,徐州221004

出　　处：《中国新药杂志》2023年第6期589-597,共9页Chinese Journal of New Drugs

摘　　要：胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)类似物已广泛用于糖尿病和肥胖症的治疗,而将GLP-1类似物与其他肠道激素如葡萄糖依赖的促胰岛素肽、胰高血糖素结合的多受体激动剂正处于临床开发阶段。与GLP-1类似物相比,多受体激动剂可发挥多重生理效应、控制血糖和降低体重的效果更好、不良反应更小,有望成为糖尿病和肥胖症的新疗法。本文对在研的肠道激素类多受体激动剂进行综述,总结其设计思路及临床表现,为多受体激动剂类药物的开发提供参考。Glucagon-like peptide-1(GLP-1)analogues have been widely used in the treatment of diabetes and obesity,and multi-receptor agonists that combine GLP-1 analogues with other intestinal hormones such as glucosedependent insulin-stimulating peptide(GIP)and glucagon(GCG)are in clinical development.Compared with GLP-1 analogues,multi-receptor agonists can exert multiple physiological effects and have better effects in controlling blood glucose and reducing body weight with fewer side effects,which are expected to be a new therapy for diabetes and obesity.In this paper,we reviewed the development of intestinal hormone multi-receptor agonists,summarized their design ideas and clinical manifestations,and provided reference for the development of multi-receptor agonists.

关 键 词：糖尿病 多受体激动剂 胰高血糖素样肽-1 肥胖症 胃肠道激素 

分 类 号：R977[医药卫生—药品]